This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CHRIS J. D. ZARAFONETIS, M.D.; WILLIAM A. STEIGER, M.D.; I. W. GINSBURG, M.D.; ARTHUR J. HEATHER, M.D.

AMA Arch Intern Med. 1953;92(2):204-215.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

MEASURES introduced for the treatment of rheumatoid arthritis have two points of major interest and value. First, any treatment which may mitigate the symptoms and contribute to the rehabilitation of persons suffering with this disorder possesses intrinsic merit. Second, the demonstration that an agent, or a combination of agents, can modify certain manifestations of rheumatoid arthritis may further contribute to the over-all knowledge of the pathologic physiology of this disease of unknown etiology. It appears warranted, therefore, to report at this time data which indicate that p-aminobenzoic acid and acetylsalicylic acid, in appropriate combination, are capable of producing beneficial effects in a significant proportion of patients with active rheumatoid arthritis.

The considerations which led to the use of this particular combination of therapeutic agents stem largely from a long-range study of the clinical effects of p-aminobenzoic acid. This substance is a member of the B-complex group of vitamins . . . [Full Text PDF of this Article]

Author Affiliations
PHILADELPHIA; WILMINGTON, DEL.

From the Department of Medicine, Temple University School of Medicine (Drs. Zarafonetis, Steiger, and Ginsburg) and the Delaware Hospital (Dr. Heather).

Footnotes
This study has been aided by a grant from an anonymous benefactor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?